Point Mutations of the c-H-ras Gene in Spontaneous Liver Tumors of Transgenic Mice Carrying the Human c-H-ras Gene
- 1 July 1998
- journal article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 26 (4) , 556-561
- https://doi.org/10.1177/019262339802600412
Abstract
Spontaneous proliferative liver lesions were found in 15 (13 males and 2 females) of 244 (122 of each sex) transgenic (Tg) mice carrying the human prototype c-H-ras gene (rasH2). The liver lesions included 3 foci of cellular alteration, 1 hepatocellular adenoma, 5 hepatocellular carcinomas, and 4 hepatic hemangiosarcomas in the males and 1 focus of cellular alteration and 1 hepatocellular carcinoma in the females. The mutation patterns of the human and endogenous mouse c-H-ras codon 61 in these proliferative liver lesions were analyzed by DNA amplification using polymerase chain reaction, single-strand conformation polymorphism (PCR-SSCP), and oligonucleotide dot blot hybridization. The hepatocellular carcinomas in 4 males and 1 female contained a point mutation in the mouse c-H-ras gene: 3, 1, and 1 carcinomas had a CAA to AAA transversion at the first base of codon 61, a CAA to CTA transversion, and a CAA to CGA transition at the second base of codon 61, respectively. No point mutations in the human c-H-ras transgene were detected in any hepatocellular carcinoma. All 4 hepatic hemangiosarcomas had a CAG to CTG transversion at codon 61 of the human c-H-ras gene, but no point mutations were detected in codon 61 of the mouse c-H-ras gene. No mutations in human or mouse c-H-ras codon 61 were detected in altered cell foci or hepatocellular adenoma. These results indicate that spontaneous liver tumors in rasH2 Tg mice contain different mutation patterns depending on the histologic type or cell origin of the tumors (i.e., hepatocellular carcinomas or hepatic hemangiosarcomas). The absence of similar mutations in foci of cellular alteration and the hepatocellular adenoma suggests that the occurrence of codon 61 point mutations is a late event in the progression of hepatocellular neoplasia in rasH2 Tg mice.Keywords
This publication has 20 references indexed in Scilit:
- Carcinogenicity Testing and the Evaluation of Regulatory Requirements for PharmaceuticalsRegulatory Toxicology and Pharmacology, 1997
- Medium-term Rat Liver Bioassay for Rapid Detection of Hepatocarcinogenic Substances.Journal of Toxicologic Pathology, 1997
- Rare Activation of the Human c‐Ha‐ras Transgene of Mice in Hemangioendothelial Sarcomas and Liver Tumors Induced by Glu‐P‐1Japanese Journal of Cancer Research, 1996
- Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of the human c-Ha-ras transgeneCarcinogenesis: Integrative Cancer Research, 1996
- Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumorsToxicology, 1995
- Marketed Human Pharmaceuticals Reported to be Tumorigenic in RodentsJournal of the American College of Toxicology, 1995
- Site-specific Mutation of the Human c-Ha-ras Transgene Induced by Dimethylbenzanthracene Causes Tissue-specific Tumors in MiceJapanese Journal of Cancer Research, 1994
- Evaluation of Reduced Protocols for Carcinogenicity Testing of Chemicals: Report of a Joint EPA/NIEHS WorkshopRegulatory Toxicology and Pharmacology, 1994
- IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassayExperimental and Toxicologic Pathology, 1992
- Liver Lesions in B6C3F1 Mice: The National Toxicology Program, Experience and PositionPublished by Springer Nature ,1987